Financial Performance - The company's revenue for Q1 2023 was CNY 473,030,518.35, representing a 27.63% increase compared to CNY 370,629,245.42 in the same period last year[5] - Net profit attributable to shareholders for Q1 2023 was CNY 138,474,386.29, a significant increase of 171.11% from CNY 51,076,948.02 in the previous year[5] - The net profit after deducting non-recurring gains and losses was CNY 125,533,224.91, up 157.67% from CNY 48,718,416.30 year-on-year[5] - The basic earnings per share for Q1 2023 was CNY 0.3236, an increase of 171.02% compared to CNY 0.1194 in the same period last year[10] - Total operating revenue for Q1 2023 reached ¥473,030,518.35, an increase of 27.7% compared to ¥370,629,245.42 in Q1 2022[19] - Operating profit for Q1 2023 was ¥149,428,037.24, up 165.7% from ¥56,213,208.39 in the same period last year[19] - Net profit attributable to the parent company for Q1 2023 was ¥138,474,386.29, a significant increase from ¥51,076,948.02 in Q1 2022, representing a growth of 171.5%[20] - Basic earnings per share for Q1 2023 were ¥0.3236, compared to ¥0.1194 in Q1 2022, reflecting a 171.5% increase[20] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3,692,458,938.45, reflecting a 4.18% increase from CNY 3,544,216,145.59 at the end of the previous year[5] - The total current assets amounted to ¥2,633,566,082.40, up from ¥2,514,310,007.04, indicating an increase of about 4.7%[15] - The total assets of the company reached ¥3,692,458,938.45, compared to ¥3,544,216,145.59 at the beginning of the year, reflecting a growth of approximately 4.2%[16] - The total liabilities decreased to ¥762,787,304.45 from ¥804,413,526.41, a reduction of approximately 5.2%[17] - Total equity attributable to shareholders increased to ¥2,929,671,634.00 from ¥2,739,802,619.18, marking a growth of 6.9%[17] Cash Flow - The company's cash and cash equivalents at the end of Q1 2023 amounted to CNY 148,591,670.00, which is a 50.16% increase from CNY 98,957,000.00 year-on-year[10] - The net cash flow from operating activities for Q1 2023 was CNY 48,269,069.80, a decrease of 7.21% compared to CNY 52,021,509.15 in the same period last year[5] - Cash generated from operating activities was ¥509,891,004.68, compared to ¥459,218,493.82 in the previous year, indicating an increase of 11.1%[21] - The net cash flow from operating activities for Q1 2023 was ¥48,269,069.80, a decrease of 1.44% compared to ¥52,021,509.15 in Q1 2022[22] - The total cash and cash equivalents at the end of Q1 2023 reached ¥1,485,916,653.31, up from ¥989,579,920.30 at the end of Q1 2022, representing a significant increase of 50.3%[23] Expenses - The company experienced a 44.05% increase in selling expenses, totaling CNY 10,568,180.00, primarily due to increased human resources and travel costs[9] - The company’s financial expenses decreased by 464.05% to -CNY 730,460.00, mainly due to increased interest income[9] - Research and development expenses for Q1 2023 were ¥80,009,904.74, up from ¥75,702,238.74 in Q1 2022, reflecting a growth of 5.4%[19] - Sales expenses increased to ¥105,681,831.55 from ¥73,365,183.75, a rise of 43.9% year-over-year[19] - Cash paid for purchasing goods and services was ¥194,127,831.33, an increase of 22.47% compared to ¥158,565,395.48 in Q1 2022[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,518[11] - The largest shareholder, Chen Zhiqiang, holds 22.37% of the shares, totaling 95,725,200 shares, with 11,500,000 shares pledged[12] Other Information - The company reported a total of CNY 12,941,161.38 in non-recurring gains and losses for Q1 2023[6] - The company did not conduct an audit for the Q1 2023 report[24]
开立医疗(300633) - 2023 Q1 - 季度财报